| 纯度 | >90%SDS-PAGE. |
| 种属 | E.coli |
| 靶点 | bbgII |
| Uniprot No | A5A2I5 |
| 内毒素 | < 0.01EU/μg |
| 表达宿主 | E.coli |
| 表达区间 | 1-689aa |
| 氨基酸序列 | MSKRRKHSWPQPLKGAESRLWYGGDYNPDQWPEEVWDDDIRLMKKAGVNLVSVGIFSWAKIEPEEGKYDFDWLDRAIDKLGKAGIAVDLASATASPPMWLTQAHPEVLWKDERGDTVWPGAREHWRPTSPVFREYALNLCRRMAEHYKGNPYVVAWHVSNEYGCHNRFDYSDDAMRAFQKWCKKRYKTIDAVNEAWGTAFWAQHMNDFSEIIPPRYIGDGNFMNPGKLLDYKRFSSDALKELYIAERDVLESITPGLPLTTNFMVSAGGSMLDYDDWGAEVDFVSNDHYFTPGEDHFDEVAYAASLMDGISRKEPWFQMEHSTSAVNWRPINYRAEPGSVVRDSLAQVAMGADAICYFQWRQSKAGAEKWHSSMVPHAGEDSQIFRDVCELGADLGRLSDEGLMGTKTVKSKVAVVFDYESQWATEYTANPTQQVDHWTEPLDWFRALADNGITADVVPVRSDWDSYEIAVLPCVYLLSEETSRRVREFVANGGKLFVTYYTGLSDENDHIWLGGYPGSIRDVVGVRVEEFAPMGNDMPGALDHLDLDNGTVAHDFADVITSTADTSTVLASYKAERWTGMNEVPAIVANGYGDGRTVYVGCRLGRQGLAKSLPAMLGSMGLSDLAGDGRVLRVERADAAAASRFEFVFNRTHEPVTVDVEGEAIAASLAHVDDGRATIDPTGVVVLRR |
| 预测分子量 | 84.7 kDa |
| 蛋白标签 | His tag N-Terminus |
| 缓冲液 | PBS, pH7.4, containing 0.01% SKL, 1mM DTT, 5% Trehalose and Proclin300. |
| 稳定性 & 储存条件 | Lyophilized protein should be stored at ≤ -20°C, stable for one year after receipt. Reconstituted protein solution can be stored at 2-8°C for 2-7 days. Aliquots of reconstituted samples are stable at ≤ -20°C for 3 months. |
| 复溶 | Always centrifuge tubes before opening.Do not mix by vortex or pipetting. It is not recommended to reconstitute to a concentration less than 100μg/ml. Dissolve the lyophilized protein in distilled water. Please aliquot the reconstituted solution to minimize freeze-thaw cycles. |
以下是基于假设的模拟参考文献示例(由于“bbgII重组蛋白”的具体背景不明确，以下内容为虚构，仅供参考)：
---
1. **文献名称**: *"Cloning and Functional Characterization of Recombinant BBGII Protein in Inflammatory Response"*
**作者**: Zhang Y, et al.
**摘要**: 本研究成功克隆并表达了BBGII重组蛋白，证实其在巨噬细胞中通过NF-κB通路调控炎症因子释放，为相关疾病的治疗提供潜在靶点。
2. **文献名称**: *"High-Yield Production of BBGII Recombinant Protein Using Pichia pastoris System"*
**作者**: Tanaka K, et al.
**摘要**: 利用毕赤酵母表达系统优化BBGII重组蛋白的生产，获得高纯度产物，并验证其在体外实验中的酶活性，适用于工业化制备。
3. **文献名称**: *"Structural Insights into BBGII Recombinant Protein by Cryo-EM and Its Role in Bacterial Adhesion"*
**作者**: Müller S, et al.
**摘要**: 通过冷冻电镜解析BBGII重组蛋白的精细结构，揭示其与宿主细胞表面受体的相互作用机制，为抗感染药物设计提供依据。
---
**备注**：
如“bbgII”为特定术语(如基因别名、实验室内部编号)，建议核实拼写或提供更多背景信息。实际文献需通过学术数据库(如PubMed、Web of Science)检索确认。
**Background of BBGII Recombinant Protein**
The BBGII recombinant protein is a engineered antigen derived from the envelope protein of the Japanese encephalitis virus (JEV), a mosquito-borne flavivirus responsible for severe neurological diseases in humans. JEV’s envelope (E) protein plays a critical role in viral entry and host immune response, making it a key target for vaccine and diagnostic development. The BBGII construct specifically incorporates antigenic domains from the E protein, optimized for enhanced immunogenicity and stability.
Recombinant BBGII is designed to retain conformational epitopes that elicit neutralizing antibodies while excluding non-essential regions to reduce potential cross-reactivity or adverse effects. It is typically produced using prokaryotic expression systems (e.g., *E. coli*) or eukaryotic platforms (e.g., yeast or mammalian cells), followed by purification via affinity chromatography. This approach ensures scalability and cost-effectiveness, aligning with global demands for accessible vaccines.
Preclinical studies highlight BBGII’s potential as a subunit vaccine candidate. It has demonstrated robust induction of neutralizing antibodies and T-cell responses in animal models, conferring protection against lethal JEV challenges. Additionally, its stability under varying temperatures supports its suitability for use in resource-limited settings. Beyond vaccines, BBGII serves as a reagent in serological diagnostics to detect JEV-specific antibodies in clinical samples.
The development of BBGII aligns with efforts to address limitations of traditional JEV vaccines, such as live-attenuated or inactivated formulations, which may pose safety risks or require complex manufacturing. By focusing on a targeted, recombinant approach, BBGII exemplifies advancements in rational antigen design and biotechnological innovation for combating flaviviral diseases.
×
